Insiders MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/02/2026 GMT			5-day change	1st Jan Change
5.540 ^USD	-2.12%		-4.97%	-2.29%

02-09	MannKind Enrolls First Patient in Study Evaluating Afrezza Inhaled Insulin in Youth	MT
02-09	MannKind announces first patient enrolled in Inhale-1st pediatric study evaluating Afrezza® for youth with newly-diagnosed type 1 diabetes (T1d)	RE

Insiders

12-18	Cartesian Therapeutics, Inc. Announces the Appointment of Adrian Bot to Board of Directors and Member of the Science and Technology Committee	CI
29/09/25	MannKind appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer	RE
29/09/25	MannKind Corporation Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, Effective September 29, 2025	CI
15/05/25	Mannkind Corporation Announces Burkhard Blank Step Down as Chief Medical Officer and Executive Vice President, Research & Development	CI
06/01/25	Mannkind Corporation Announces Resignation of Lauren Sabella as Executive Vice President, Operations, Effective July 18, 2025	CI
06/01/25	Dominic Marasco Joins MannKind Corporation as President, Endocrine Business Unit	CI
14/08/24	Mannkind Corporation Announces Board Changes, September 30, 2024	CI
26/03/24	MannKind CFO Binder to Retire in April, Names New CFO	MT
26/03/24	MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	CI
18/12/23	Mannkind Insider Sold Shares Worth $801,928, According to a Recent SEC Filing	MT
24/05/23	MannKind Hires Burkhard Blank as CMO	MT
24/05/23	Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer	CI
27/03/23	MannKind Appoints Lauren Sabella as COO	MT
27/03/23	Lauren Sabella Joins MannKind Corporation as Executive Vice President, Chief Operating Officer	CI
26/09/22	Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022	CI
10/12/20	MannKind Corporation Appoints James S. Shannon as the Chairman of the Board of Directors	CI
30/11/20	MannKind Corporation Appoints Sabrina Kay Ed.D. to Its Board of Directors	CI
28/08/20	MannKind Corporation Announces Resignation of David Kendall as Chief Medical Officer	CI
20/07/20	Mannkind Corporation Appoints Alejandro Galindo as Chief Commercial Officer, Effective August 4, 2020	CI
10/04/20	MannKind Corporation Announces Retirement of Nordhoff from the Audit Committee and Board	CI
24/03/20	Jennifer Grancio Joins Mannkind's Board of Directors	CI
21/11/19	Mannkind Appoints Tony Hooper to its Board of Directors and Member of the Audit Committee, Effective January 1, 2020	CI
27/11/18	MannKind Appoints Christine Mundkur to its Board of Directors	CI
06/02/18	MannKind Corporation Appoints David M. Kendall as Chief Medical Officer, Effective February 12, 2018	CI
30/10/17	Mannkind Corporation Announces Resignation of Matthew J. Pfeffer as Director	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Insiders MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Insiders

Filters